Description

Alcon Unlocks A New Lens Opportunity — RxSight Partnership Targets Adjustable IOLs!

Alcon’s second quarter 2026 results reflected modest growth supported by a broad-based contribution across its Surgical and Vision Care franchises. Sales increased 7% year-over-year to $2.8 billion, with surgical sales rising 7% and Vision Care sales also up 7%. Equipment sales, particularly from the UNITY platform, grew 25%, underscoring the commercial success of recent innovations. Implantables reported 1% growth, with intraocular lenses (IOLs) up 2% despite new competitive entrants. The PanOptix trifocal IOL family, especially the PanOptix Pro variant, showed robust adoption in the U.S. and expanding international rollout, partially offsetting softness elsewhere in implantables. Contact lenses experienced 5% growth, driven by share gains in dailies and reusables segments, supported by products like TOTAL1, PRECISION1, TOTAL30 multifocal, and PRECISION7. The ocular health segment notably grew 12%, fueled by strong uptake of the prescription dry eye therapy TRYPTYR and the consumer brand Systane.